BIA response to Health Secretary's plan to contain and control AMR
Steve Bates OBE, CEO of the BIA said:
“It’s great to see the UK government and NHS committed to exploring a new payment model for antibiotics in our market. The UK took a lead in putting Anti Microbial Resistance (AMR) on the global agenda and it’s really good to see it taking a first mover advantage on innovative pricing and reimbursement for AMR.
“Ensuring these incentives work for innovative small biotech companies and their investors is vital as we continue to see established players divesting from this area.
“The BIA will continue to work in partnership with the UK government to explain the incentives behind the headlines to potential investors and management teams - starting at our Strategic Technologies event in the City of London this afternoon- and provide feedback to the UK government as to whether they are moving the investment dial.
“Since the UK market is only 3% of the global drugs market and AMR drugs are developed for a global market, the biggest value of this UK move will be its continued political leadership to inspire other countries to develop reimbursement mechanisms for drug developers in AMR suitable for their own health systems."
Keep up to date with our Strategic Technologies event on twitter using #BIAStrategicTechnologies
Contact: Jack Fellows, BIA Communications Manager email@example.com 02076302196
About the BioIndustry Association
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.